6-dehydrotestosterone (6-DHT) is a potent androgen that is a metabolite of testosterone. It is synthesized by the enzyme 5α-reductase, which converts testosterone to dihydrotestosterone (DHT), and then by the enzyme 3β-hydroxysteroid dehydrogenase, which converts DHT to 6-DHT. 6-DHT is a potent agonist of the androgen receptor, and it has been shown to have a variety of effects, including promoting muscle growth, masculinization, and prostate growth. 6-DHT is studied because of its potential role in male pattern baldness and prostate cancer. It is also being investigated as a potential therapeutic agent for a variety of conditions, including hypogonadism, muscle wasting, and osteoporosis.'
6-dehydrotestosterone : A 17beta-hydroxy steroid that is testosterone that contains an additional double bond between positions 6 and 7. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
| ID Source | ID |
|---|---|
| PubMed CID | 17209 |
| CHEBI ID | 29117 |
| SCHEMBL ID | 3364701 |
| MeSH ID | M0081084 |
| Synonym |
|---|
| delta(sup 6)-testosterone |
| 6,7-dehydrotestosterone |
| nsc 75560 |
| androsta-4,6-dien-3-one, 17-hydroxy-, (17beta)- |
| (17-beta)-17-hydroxyandrosta-4,6-dien-3-one |
| (17beta)-17-hydroxyandrosta-4,6-dien-3-one |
| einecs 219-623-6 |
| androsta-4,6-dien-3-one, 17-beta-hydroxy- |
| androsta-4,6-dien-17-beta-ol-3-one |
| androsta-4,6-dien-3-one, 17-hydroxy-, (17-beta)- |
| 6-dehydrotestosterone |
| 6,7-didehydrotestosterone |
| CHEBI:29117 |
| 17beta-hydroxyandrosta-4,6-dien-3-one |
| nsc-75560 |
| nsc75560 |
| 2484-30-2 |
| androsta-4, 17-hydroxy-, (17.beta.)- |
| (8r,9s,10r,13s,14s,17s)-17-hydroxy-10,13-dimethyl-1,2,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-3-one |
| SCHEMBL3364701 |
| LMST02020082 |
| 17-hydroxy-4,6-androstadiene-3-one |
| delta(6)-testosterone |
| 4p45k0o2lx , |
| unii-4p45k0o2lx |
| 2352-19-4 |
| 17b-hydroxy-4,6-androstadiene-3-one |
| 17-hydroxyandrosta-4,6-dien-3-one # |
| UMDCOKNNLDEKJB-DYKIIFRCSA-N |
| 17beta-hydroxyandrosta-4,6-dien-3-one (?6-testosterone) |
| .delta.6-testosterone |
| testosterone impurity i [ep impurity] |
| Q27109951 |
| 6-dehydrotestosterone acetate |
| (8r,9s,10r,13s,14s,17s)-17-hydroxy-10,13-dimethyl-1,2,8,9,10,11,12,13,14,15,16,17-dodecahydro-3h-cyclopenta[a]phenanthren-3-one |
| A903335 |
| (1s,3as,3br,9ar,9bs,11as)-1-hydroxy-9a,11a-dimethyl-1h,2h,3h,3ah,3bh,7h,8h,9h,9ah,9bh,10h,11h,11ah-cyclopenta[a]phenanthren-7-one |
| 17?-hydroxyandrosta-4,6-dien-3-one (?6-testosterone) |
| DTXSID801043247 |
| Class | Description |
|---|---|
| 3-oxo-Delta(4) steroid | A 3-oxo steroid conjugated to a C=C double bond at the alpha,beta position. |
| 17beta-hydroxy steroid | A 17-hydroxy steroid in which the hydroxy group at position 17 has a beta-configuration. |
| enone | An alpha,beta-unsaturated ketone of general formula R(1)R(2)C=CR(3)-C(=O)R(4) (R(4) =/= H) in which the C=O function is conjugated to a C=C double bond at the alpha,beta position. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 9 (64.29) | 18.7374 |
| 1990's | 4 (28.57) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (7.14) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (11.43) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 15 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||